Creating a Hybrid Clinical Trial

Virtual clinical trials gained traction during the covid-19 pandemic when on-site studies became hazardous. Researchers were forced to move some of their research off-site, and they learned about the benefits along the way.

This kind of study shortens enrollment, improves patient retention, and streamlines patient visits. They aren’t perfect, of course. Decentralized trials are less intimate, so research subjects might not get the face time they need to interact with study staff.

Patients can miss important symptoms and are often required to use wearable devices that haven’t been validated. Hybrid clinical trials provide a balanced clinical trial environment, absorbing the benefits of both forms of research while negating some of the disadvantages.

Understanding the Hybrid Approach

Hybrid models are remarkably pragmatic. They move the trial off-site, allowing patients to communicate and record data via digital technologies. They can make room for both real-world and remote data collection, so researchers can strike the right balance.

If patients are operating their own diagnostic equipment, researchers can improve their coverage through on-site, centralized monitoring.

In-home services are often relied upon, so enrolment rates grow as the patient burden shrinks. This approach is only possible thanks to wearable devices that can manage digital endpoints.

The industry has broadened massively, so researchers can now find the precise validation their trials demand, no matter their therapeutic areas. Hybrid trials lift the patient burden by reducing travel and in-person visits.

Modern trials are becoming increasingly patient-centric. Research subjects often participate in the study design, so they have control over its impact on their lives.

With a bespoke trial structure that’s supported by remote technologies, researchers can fine-tune their in-person meetings uniquely for every study. That means happier patients and happier scientists.

Virtual studies can even enhance data collection, giving trials a robust and interpretable way to measure outcomes. If data quality falls, the hybrid approach gives pharmaceutical companies the time and on-site visits required to do regular testing.

How to Adopt a Hybrid Model

In the past, clinical studies have been handled like assembly lines—They’ve remained the same no matter the trial or desired outcome. Running a hybrid trial requires researchers to rethink and look at and rethink the impacts of their study designs. Every study is bespoke, but they carry a few core benefits:

• Hybrid designs are more inclusive, so researchers can create a wider sample.
• Participants can be monitored more regularly.
• Drug development becomes more streamlined, giving researchers a faster way to approve new therapies.
• Researchers gain extra opportunities to make their studies more patient-centric.

Hybrid studies aren’t flawless. They introduce several significant challenges.

• Patient engagement and accessibility aren’t always what you might like them to be. This can be managed during patient recruitment screening
• Data collected through wearable devices can be inaccurate. Regular in-person visits and telemedicine can resolve the problem.
• Digital data must be carefully controlled to prevent unwanted sharing. Researchers will need to use platforms and apps that offer enough data security to meet regulatory standards.
• If poorly designed, the communication between healthcare providers and patients can be inadequate, so include regular face-to-face consultations in your schedule.

Managing Treatment Effects Remotely

Decentralized trials might reduce patient travel times, but they require plenty of data collection on behalf of the subject. Digital wearables can deepen your understanding of the patient experience while improving your knowledge of how your therapy operates in everyday life.

They do create their own problems, though. If the wearables haven’t proven themselves in their own clinical research, your data will be muddied, rendering your entire trial useless.

If your wearables don’t meet regulatory standards for reliability and robustness, no amount of remote data collection precision can resolve the problem. Wearables aren’t approved by the FDA, but they are cleared.

They’re moderate-risk devices that pose an enormous risk to the clarity of your outcome. You can overcome some of those barriers by adding in-person testing to your decentralized elements. Patient acceptance is another issue that should be handled before your clinical study begins.

Hybrid trials allow you to enjoy the best of both worlds. They can provide abundant data, and if you churn that information by cleaning and checking validity, you can achieve far more robust results than centralized trials.